TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03600779

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: inhomogeneous Magnetisation Transfer (ihMT) sequence
Description: robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inhomogeneous Magnetisation Transfer (ihMT) sequence
Description: robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T
Description: robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T
Description: robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T
Study: NCT00457015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ecallantide
Description: dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Saline (PBS), pH 7.0
Description: given as three 1mL subcutaneous injections.
Study: NCT00466466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.
Study: NCT00075023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gel
Study: NCT04503954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic disease self-management program
Description: The chronic disease self-management program is based on the self-efficacy theory for improving health behavior, by the solve health problem skill, health life style, emotion management skill, improve intention of health condition in people with chronic disease.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General psychiatric intervention
Description: General psychiatric intervention contains the activities in psychiatric center.
Study: NCT03471702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart External Drain - SED
Description: Aqueduct's Smart External Drain (SED) is a gravity based system which utilizes a proprietary reference shroud which eliminates the need for manual adjustment of the system in the external management of CSF drainage.
Study: NCT01243710

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taurolidine with heparin (500 units/ ml)
Description: Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taurolidine with heparin (500 units/ ml)
Description: Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
Study: NCT00842426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program (SM)
Description: Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.~During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care management program (CM)
Description: In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.~During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support.
Study: NCT02443363

Intervention type: OTHER
Intervention: Estimating of formula MDRD, CKD-EPI, Cockroft-Gault,

Intervention type: DEVICE
Intervention: Tanita BC 418- Bioelectrical impedance analysis
Description: The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
Study: NCT01833637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APN Intervention
Description: Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
Study: NCT04933331

Intervention type: DRUG
Intervention: Curodont Repair Fluoride Plus
Description: Self-assembling peptide that integrates calcium and phosphate ions into the same hydroxyapatite that the enamel is made of through biomimetic re-mineralization. Amino acid sequence: CH3,COQQRFEWEFEQQ,NH2.

Intervention type: DRUG
Intervention: Curodont Repair Fluoride Plus
Description: Self-assembling peptide that integrates calcium and phosphate ions into the same hydroxyapatite that the enamel is made of through biomimetic re-mineralization. Amino acid sequence: CH3,COQQRFEWEFEQQ,NH2.

Intervention type: DEVICE
Intervention: Silver Diamine Fluoride
Description: Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity. SDF works by killing pathogenic organisms and hardens softened dentin making it more acid and abrasion resistant. The ADA recommends the use of SDF in treating early lesions.

Intervention type: DEVICE
Intervention: Silver Diamine Fluoride
Description: Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity. SDF works by killing pathogenic organisms and hardens softened dentin making it more acid and abrasion resistant. The ADA recommends the use of SDF in treating early lesions.

Intervention type: DEVICE
Intervention: Glass Ionomer Sealant
Description: A hydrophilic type of sealant material made with water, polymeric acid, and glass power. These sealants release fluoride over time which also helps protect against and repair initial caries lesions. The ADA recommends the use of sealants in treating occlusal early lesions.

Intervention type: DEVICE
Intervention: Glass Ionomer Sealant
Description: A hydrophilic type of sealant material made with water, polymeric acid, and glass power. These sealants release fluoride over time which also helps protect against and repair initial caries lesions. The ADA recommends the use of sealants in treating occlusal early lesions.

Intervention type: DEVICE
Intervention: Fluoride varnish
Description: 2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.

Intervention type: DEVICE
Intervention: Fluoride varnish
Description: 2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.

Intervention type: DEVICE
Intervention: Fluoride varnish
Description: 2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.

Intervention type: DEVICE
Intervention: Fluoride varnish
Description: 2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.

Intervention type: DRUG
Intervention: Fluoride toothpaste
Description: Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
Study: NCT05741671

Intervention type: OTHER
Intervention: Questionnaire
Description: Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.
Study: NCT04100252

Intervention type: OTHER
Intervention: AFI via transabdominal ultrasonography
Description: AFI via transabdominal ultrasonography was performed at the time of diagnosis.
Study: NCT04933331

Intervention type: DRUG
Intervention: Fluoride toothpaste
Description: Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.

Intervention type: DRUG
Intervention: Fluoride toothpaste
Description: Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.

Intervention type: DRUG
Intervention: Fluoride toothpaste
Description: Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
Study: NCT04442828

Intervention type: DIAGNOSTIC_TEST
Intervention: Use of 3D echocardiography in patient follow-up
Description: Patients will undergo clinical and echocardiographic examination including detailed 3D echocardiography at study inclusion and at least one follow-up visit.

Intervention type: DIAGNOSTIC_TEST
Intervention: Use of 3D echocardiography in patient follow-up
Description: Patients will undergo clinical and echocardiographic examination including detailed 3D echocardiography at study inclusion and at least one follow-up visit.
Study: NCT00131248

Intervention type: DRUG
Group type: OTHER
Intervention: Metaclopramide

Intervention type: DRUG
Group type: OTHER
Intervention: Metaclopramide
Study: NCT01018433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-SIB
Description: Treatment for self-injurious behaviors; study psychotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Can include other psychotherapy and pharmacotherapy
Study: NCT02603120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/DTG/3TC
Description: 600/50/300 mg FDC tablets administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/DTG/3TC Placebo
Description: Tablets administered orally once daily without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF Placebo
Description: Tablets administered orally once daily without regard to food
Study: NCT03094234

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8mm-TIPS
Description: Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic variceal ligation (EVL)
Description: Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Appropriate dose of propranolol was administered to the patients.
Study: NCT04216277

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Description: In addition to usual care diagnostic and handling of acute respiratory tract infections in general practice to attending physician in the intervention arm has access to antibiotic stewardship by a procalcitonin point-of-care test. The following criteria for initiating og withholding antibiotics will be used.~* Antibiotics treatment is recommended with Procalcitonin levels above 0.25 ng/ml~* Antibiotic treatment is discouraged if Procalcitonin levels are below 0.25 ng/ml
Study: NCT02218281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C2Q-Teen app
Description: Commit to Quit (C2Q)-Teen app provides smoking cessation assistance incorporating mindfulness training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI's QuitSTART app
Description: NCI's smoking cessation app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written smoking cessation materials only
Description: Receipt of written smoking cessation materials
Study: NCT00529997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stabilimax NZ® Dynamic Spine Stabilization System
Description: Surgical Implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stabilimax NZ® Dynamic Spine Stabilization System
Description: Surgical Implantation
Study: NCT03186677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
Description: ISU304/CB2679d/Dalcinonacog alfa 75\~150 IU/kg by intravenous or subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
Description: ISU304/CB2679d/Dalcinonacog alfa 75\~150 IU/kg by intravenous or subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
Description: ISU304/CB2679d/Dalcinonacog alfa 75\~150 IU/kg by intravenous or subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
Description: ISU304/CB2679d/Dalcinonacog alfa 75\~150 IU/kg by intravenous or subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
Description: ISU304/CB2679d/Dalcinonacog alfa 75\~150 IU/kg by intravenous or subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BeneFIX
Description: BeneFIX 75 IU/kg, intravenous administration
Study: NCT04135430

Intervention type: OTHER
Intervention: Survey
Description: practice of an updated questionnaire at D0, D2 and D7
Study: NCT01916837

Intervention type: OTHER
Intervention: Sampling of tumor tissue
Description: Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery

Intervention type: OTHER
Intervention: Sampling of tumor tissue after breast cancer surgery
Description: Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery

Intervention type: PROCEDURE
Intervention: Sampling of tumor tissue after breast cancer surgery
Description: Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
Study: NCT04077307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karonudib
Description: First part of the study - four different dose cohorts Extension part of the study - karonudib BID (twice a week) and Idarubicin days 1-3.
Study: NCT01750385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no antibiotic prophylaxis
Description: These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: second-generation cephalosporin
Description: These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
Study: NCT01351935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVL-292
Description: 125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops
Study: NCT01408992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Audiometry
Description: Standard hearing test performed by audiologists

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai-Five Minute Hearing Test
Description: All subjects will be interviewed with Thai-Five Minute Hearing Test
Study: NCT04064502

Intervention type: DIAGNOSTIC_TEST
Intervention: CHRONIC ANKLE INSTABILITY AND ASSOCIATED FACTORS:
Description: Questionnaire including sociodemographic information, general medical condition, history of orthopedic surgery, pain intensity, and the number of painful areas of the foot.
Study: NCT04082871

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication management review
Description: The researcher screened each completed an MMR template and verified that all information in each patient template was complete. A classification system was then used to identify the TRPs which either actually or potentially interfered with the clinical outcomes for each patient.\[19\] This system was explained in detail and applied successfully in many previous studies.\[10, 14, 20\] The researcher then identified TRPs for each patient in both groups using evidence-based medicine. The TRPs including unneeded drug treatment, untreated condition/s, efficacy/effectiveness issues, safety issues, inadequate knowledge, inappropriate adherence to pharmacological therapy, inappropriate adherence to self-care activities and miscellaneous problems.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication management review
Description: The researcher screened each completed an MMR template and verified that all information in each patient template was complete. A classification system was then used to identify the TRPs which either actually or potentially interfered with the clinical outcomes for each patient.\[19\] This system was explained in detail and applied successfully in many previous studies.\[10, 14, 20\] The researcher then identified TRPs for each patient in both groups using evidence-based medicine. The TRPs including unneeded drug treatment, untreated condition/s, efficacy/effectiveness issues, safety issues, inadequate knowledge, inappropriate adherence to pharmacological therapy, inappropriate adherence to self-care activities and miscellaneous problems.
Study: NCT01206062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive control of SBP
Description: Participants in the Intensive arm have a goal of SBP \<120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics~Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard control of SBP
Description: Participants in the Standard BP arm have a goal of SBP \<140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Study: NCT02500680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MER4101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MER4101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MER4101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MER4101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MER4101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MER4101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MER4101

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine
Description: Fluzone quadrivalent Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine
Description: Fluzone quadrivalent Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine
Description: Fluzone quadrivalent Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine
Description: Fluzone quadrivalent Influenza Vaccine
Study: NCT02318862

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
Study: NCT01819051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOE Antimicrobial Plasma Treatment System
Description: Plasma applied to great toenail 1X/week for three weeks
Study: NCT00670319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene HCL
Description: Raloxifene HCL 60 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene HCL
Description: Raloxifene HCL 120 mg orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tab orally per day